|
1
|
National Comprehensive Cancer Network
(NCCN), . Clinical practice guidelines in oncology: Rectal Cancer.
Version 2.2024.
|
|
2
|
Benson AB, Venook AP, Al-Hawary MM, Arain
MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Dilawari RA, Engstrom
PF, et al: Rectal cancer, version 2.2022, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 20:1129–1161. 2022.
View Article : Google Scholar
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
4
|
International Agency for Research on
Cancer (IARC), . Global cancer observatory: Cancer today. IARC;
Lyon: 2022
|
|
5
|
World cancer research fund/American
ınstitute for cancer research, . Diet, nutrition, physical activity
and colorectal cancer. Continuous Update Project Expert Report.
2018.
|
|
6
|
Bouvard V, Loomis D, Guyton KZ, Grosse Y,
Ghissassi FE, Benbrahim-Tallaa L, Guha N, Mattock H and Straif K;
International Agency for Research on Cancer Monograph Working
Group, : Carcinogenicity of consumption of red and processed meat.
Lancet Oncol. 16:1599–1600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Botteri E, Borroni E, Sloan EK, Bagnardi
V, Bosetti C, Peveri G, Santucci C, Specchia C, van den Brandt P,
Gallus S and Lugo A: Smoking and colorectal cancer risk: An overall
and dose-response meta-analysis. Ann Oncol. 31:545–559. 2020.
|
|
8
|
Keum N and Giovannucci E: Global burden of
colorectal cancer: Emerging trends, risk factors and prevention
strategies. Nat Rev Gastroenterol Hepatol. 16:713–732. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Glynne-Jones R, Wyrwicz L, Tiret E, Brown
G, Rödel C, Cervantes A and Arnold D; ESMO Guidelines Committee, :
Rectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 28 (Suppl):iv22–iv40. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Gijn W, Marijnen CAM, Nagtegaal ID,
Kranenbarg EM, Putter H, Wiggers T, Rutten HJT, Påhlman L,
Glimelius B and van de Velde CJH; Dutch Colorectal Cancer Group, :
Preoperative radiotherapy combined with total mesorectal excision
for resectable rectal cancer: 12-year follow-up of the multicentre,
randomised Dutch TME trial. Lancet Oncol. 12:575–582. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bosset JF, Collette L, Calais G, Mineur L,
Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier
JC; EORTC Radiotherapy Group Trial 22921, : Chemotherapy with
preoperative radiotherapy in rectal cancer. N Engl J Med.
355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peters GJ, Backus HH, Freemantle S, van
Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J,
Calvert AH, Marsh S, et al: Induction of thymidylate synthase as a
5-fluorouracil resistance mechanism. Biochim Biophys Acta.
1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Houghton JA, Tillman DM and Harwood FG:
Ratio of 5-fluorouracil incorporation into RNA and DNA of human
colon carcinoma cells determines cytotoxicity. Cancer Res.
55:611–617. 1995.
|
|
16
|
Gross E, Busse B, Riemenschneider M,
Neubauer S, Seck K, Klein HG, Kiechle M, Lordick F and Meindl A:
Strong association of a common dihydropyrimidine dehydrogenase gene
polymorphism with fluoropyrimidine-related toxicity in cancer
patients. PLoS One. 3:e40032008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thorn CF, Marsh S, Carrillo MW, McLeod HL,
Klein TE and Altman RB: PharmGKB summary: Fluoropyrimidine
pathways. Pharmacogenet Genomics. 21:237–242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Paulsen NH, Vojdeman F, Andersen SE,
Bergmann TK, Ewertz M, Plomgaard P, Hansen MR, Esbech PS, Pfeiffer
P, Qvortrup C and Damkier P: DPYD genotyping and dihydropyrimidine
dehydrogenase (DPD) phenotyping in clinical oncology. A clinically
focused minireview. Basic Clin Pharmacol Toxicol. 131:325–346.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meulendijks D, Henricks LM, Sonke GS,
Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA,
Marinaki AM, Sanderson JD, et al: Clinical relevance of DPYD
variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as
predictors of severe fluoropyrimidine-associated toxicity: A
systematic review and meta-analysis of individual patient data.
Lancet Oncol. 16:1639–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amstutz U, Henricks LM, Offer SM,
Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle
KE, Diasio RB and Schwab M: Clinical pharmacogenetics
ımplementation consortium (CPIC) guideline for dihydropyrimidine
dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.
Clin Pharmacol Ther. 103:210–216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deenen MJ, Meulendijks D, Cats A,
Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H,
Mandigers CM, Soesan M, et al: Upfront genotyping of DPYD*2A to
individualize fluoropyrimidine therapy: A safety and cost analysis.
J Clin Oncol. 34:227–234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lunenburg CATC, van der Wouden CH,
Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk
AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, et al: Dutch
pharmacogenetics working group (DPWG) guideline for the gene-drug
interaction of DPYD and fluoropyrimidines. Eur J Hum Genet.
28:508–517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Henricks LM, Lunenburg CATC, de Man FM,
Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A,
Dezentjé VO, Imholz ALT, et al: DPYD genotype-guided dose
individualisation of fluoropyrimidine therapy in patients with
cancer: A prospective safety analysis. Lancet Oncol. 19:1459–1467.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
European Medicines Agency (EMA), .
Fluorouracil and fluorouracil-related substances (capecitabine,
tegafur and flucytosine): Direct healthcare professional
communication on pre-treatment testing to identify DPD-deficient
patients at increased risk of severe toxicity. EMA; Amsterdam:
2020
|
|
25
|
de Moraes FCA, de Almeida Barbosa AB, Sano
VKT, Kelly FA and Burbano RMR: Pharmacogenetics of DPYD and
treatment-related mortality on fluoropyrimidine chemotherapy for
cancer patients: a meta-analysis and trial sequential analysis. BMC
Cancer. 24:12102024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
National Cancer Institute (NCI), . Common
Terminology Criteria for Adverse Events (CTCAE). Version v6.0.U.S.
Department of Health and Human Services; 2025
|
|
27
|
Morel A, Boisdron-Celle M, Fey L,
Lainé-Cessac P and Gamelin E: Identification of a novel mutation in
the dihydropyrimidine dehydrogenase gene in a patient with a lethal
outcome following 5-fluorouracil administration and the
determination of its frequency in a population of 500 patients with
colorectal carcinoma. Clin Biochem. 40:11–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Morel A, Boisdron-Celle M, Fey L, Soulie
P, Craipeau MC, Traore S and Gamelin E: Clinical relevance of
different dihydropyrimidine dehydrogenase gene single nucleotide
polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther.
5:2895–2904. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Madi A, Fisher D, Maughan ST, Colley JP,
Meade AM, Maynard J, Humphreys V, Wasan H, Adams RA, Idziaszczyk S,
et al: Pharmacogenetic analyses of 2183 patients with advanced
colorectal cancer; potential role for common dihydropyrimidine
dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer.
102:31–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grothey A, Sobrero AF, Shields AF, Yoshino
T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, et al:
Duration of adjuvant chemotherapy for stage III colon cancer. N
Engl J Med. 378:1177–1188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hagiwara Y, Yamamoto Y, Inagaki Y,
Tomisaki R, Tsuji M, Fukuda S, Fukuda S, Onoda T, Suzuki H, Niisato
Y, et al: Severe gastrointestinal disorder due to capecitabine
associated with dihydropyrimidine dehydrogenase deficiency: A case
report and literature review. Intern Med. 61:2449–2455. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Inoue F, Yano T, Nakahara M, Okuda H,
Amano H, Yonehara S and Noriyuki T: Cytomegalovirus enterocolitis
in a patient with dihydropyrimidine dehydrogenase deficiency after
capecitabine treatment: A case report. Int J Surg Case Rep.
56:55–58. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ragia G, Maslarinou A, Atzemian N, Biziota
E, Koukaki T, Ioannou C, Balgkouranidou I, Kolios G, Kakolyris S,
Xenidis N, et al: Implementing pharmacogenetic testing in
fluoropyrimidine-treated cancer patients: DPYD genotyping to guide
chemotherapy dosing in Greece. Front Pharmacol. 14:12488982023.
View Article : Google Scholar : PubMed/NCBI
|
